AbbVie has announced positive topline results from its Phase 3 LUNA study evaluating atogepant for the preventive treatment of menstrual migraine in adults. Atogepant, sold as Qulipta in the US and Aquipta in the EU, is a calcitonin gene-related peptide receptor antagonist already approved
London stocks closed lower on Tuesday as Bank of England Governor Andrew
Chancellor John Healey is set to pump £150m into start-ups across the
Reform UK leader Nigel Farage has moved to contain the fallout from
